hrp0086p1-p214 | Diabetes P1 | ESPE2016

Analysis of Short-Term Efficacy of MiniMed 640G with SmartGuard in Pediatric Patients with Type 1 Diabetes

Villafuerte Beatriz , Martin-Frias Maria , Yelmo Rosa , Roldan Belen , Angeles Alvarez M. , Barrio Raquel

Background: Fear of hypoglycemia is a major constraint on achieving a good metabolic control in T1D. Sensor augmented insulin pump therapy with threshold-suspended features (MiniMed 640G-SG) might alleviate burden of hypoglucemia and improve outcomes.Objective and hypotheses: Evaluate the effectiveness of this system to prevent day and night hypoglycemia and its impact on HbA1c in a pediatric population with T1D.Method: Descriptive...

hrp0084p2-449 | Growth | ESPE2015

Risk for Non-Alcoholic Fatty Liver Disease in Young Adults Born Preterm

Breij Laura M , Kerkhof Gerthe F , Hokken-Koelega Anita C S

Background: Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome. Accelerated catch-up in weight during infancy in subjects born term has been associated with increased risk for NAFLD in adulthood, but this association has not been studied in subjects born preterm.Objective and hypotheses: To investigate the associations of birth weight, gain in weight for length and accelerated catch-up in weight in the...

hrp0095fc2.4 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Patient-reported outcomes from a randomized open-label phase 3 trial comparing burosumab vs conventional therapy in children with X-linked hypophosphatemia: results from the 24-week treatment extension period

Padidela Raja , Whyte Michael P , Glorieux Francis H , Munns Craig F , Ward Leanne M , Nilsson Ola , Portale Anthony A , Simmons Jill H , Namba Noriyuki , Cheong Hae Il , Pitukcheewanont Pisit , Sochett Etienne , Högler Wolfgang , Muroya Koji , Tanaka Hiroyuki , Gottesman Gary S , Biggin Andrew , Perwad Farzana , Williams Angela , Nixon Annabel , Sun Wei , Chen Angel , Skrinar Alison , Imel Erik A

In a randomized open-label phase 3 trial in 62 children (1–12 years) with X-linked hypophosphatemia (XLH) (NCT 02915705), switching from conventional therapy (oral phosphate plus active vitamin D) to burosumab, a monoclonal antibody targeting fibroblast growth factor 23, significantly improved serum phosphate concentration, rickets, lower-extremity deformities, growth, mobility, and patient-reported outcomes (PROs) at 64 weeks. Children in Europe, USA, Canada, and Australia wh...

hrp0092rfc11.3 | Pituitary, Neuroendocrinology and Puberty Session 2 | ESPE2019

Polycystic Ovarian Syndrome in Adolescents: Utilising Discovery Proteomics and the Search for to Identify Novel Non-Invasive Biomarkers

Gunn Harriet , Forysth Vhari , Hällqvist Jenny , Viner Russell , Mills Kevin , Steinbeck Katharine

Background: Polycystic ovarian syndrome (PCOS) is common, affecting up to one-fifth of females. PCOS is associated with significant comorbidity including metabolic dysfunction, pro-inflammation and mood disorders. Despite this, it is poorly understood, and diagnosis and management remain challenging in adolescents. Proteomics enables the better understanding of disease mechanisms and facilitates the identification of novel biomarkers.<st...

hrp0094p2-254 | Growth hormone and IGFs | ESPE2021

Clinic, laboratory and prognostic findings of patients who are diagnosed by Kowarski syndrome (biologically inactive growth hormone)

Gokcehan Zevker Emine , Keskin Mehmet , Karaoglan Murat , Aytac Kaplan Emel H ,

Objective: The clinical, laboratory and prognostic findings of the patients diagnosed with Kowarski Syndrome (biologically inactive growth hormone) were evaluated between February 2009 and February 2019 in order to contribute to literature.Materals and Methods: 110 cases diagnosed with Kowarski syndrome between February 2009 and February 2019 were evaluated retrospectively. 97 cases continued to work. 92 cases at least one year, 62 cases...

hrp0086p2-p666 | Growth P2 | ESPE2016

Usefulness of Growth Hormone Transient Treatment Suspension in Prepubertal Children Treated with Growth Hormone

Martinez Barahona Maria , Cecenarro Laura , Murillo Valles Marta , Luisa Granada Ybern M. , Ropero Ramos Esther , Bel Comos Joan

Background: The primary goal of treatment is to achieve a final height within the normal range and avoid the physical and psychological consequences of short stature (SS). If after a time, treatment efficacy criteria are not achieved, it is necessary to revalue its usefulness. There is no consensus about which conduct should be adopted in these cases. An alternative, is the suspension of rhGH treatment and evaluate the clinical and biochemical results to decide to continue or ...

hrp0084p2-223 | Bone | ESPE2015

Refractory Hypercalcaemia of Malignancy: Responsiveness to Denosumab and Zoledronate

Giri Dinesh , Ramakrishnan Renuka , Hayden James , Brook Lynda , Das Urmi , Mughal M Zulf , Selby Peter , Dharmaraj Poonam , Senniappan Senthil

Background: Hypercalcaemia secondary to malignancy is rare in children and adolescents. Parathyroid hormone related peptide (PTH-rP) secreted by malignant cells increases bone resorption and renal calcium retention causing hypercalcaemia. We report 2 cases of hypercalcaemia of malignancy refractory to treatment with pamidronate and corticosteroids but responsive to treatment with Denosumab and Zoledronic acid.Case 1: A 17-year-old boy with epidermolysis ...

hrp0097p1-247 | Fat, Metabolism and Obesity | ESPE2023

Th17 lymphocytes and peripheral complete blood count alterations in obese children

Artemniak-Wojtowicz Dorota , M. Kucharska Anna , Stelmaszczyk-Emmel Anna , Majcher Anna , Rumińska Małgorzata , Pyrżak Beata

Introduction: Obesity is considered one of the most common chronic diseases worldwide which is associated with chronic, low-grade, sterile inflammation. It leads to variable changes in metabolic and hormonal homeostasis. The aim of our study was to evaluate the impact of obesity associated chronic inflammation on peripheral complete blood count alterations.Material and Methods: 27 overweight/obese and 15 normal-weight ch...

hrp0097p1-262 | Fat, Metabolism and Obesity | ESPE2023

16p11.2 microdeletion: a common copy number variation (CNV) identified in a Portuguese pediatric cohort with syndromic obesity.

Rosmaninho-Salgado Joana , B. Sousa Sergio , M. Pires Luis , Ferreira Susana , B. Melo Joana , M. Carreira Isabel , M. Saraiva Jorge

Background: 16p11.2 microdeletion is most common chromosomal anomaly associated with syndromic obesity. The presence of a large number of flanking segmental duplications/low-copy repeat sequences with a high degree of sequence identity in the short arm of chromosome 16 (16p) leads to recurrent deletions and duplications as a consequence of non-allelic homologous recombination. A recurrent 600kb microdeletion is one of the most frequent genomic imbalances in 16...

hrp0089p3-p003 | Adrenals and HPA Axis P3 | ESPE2018

Nelson’s Syndrome after Bilateral Adrenalectomy for Cushing’s Disease in Pediatric Age – Report of a Case

Machado Catarina M , Leite Ana L , Sousa Ana , Almeida Lucia , Campos Rosa Armenia , Oliveira Maria Joao , Marques Jorge Sales

Introduction: Nelson’s syndrome is a potentially severe complication of bilateral adrenalectomy, a radical procedure performed in the treatment of hypercortisolism in Cushing’s disease (CD). We report a case of CD in pediatric age submitted to bilateral adrenalectomy with subsequent Nelson’s syndrome.Case report: Male, 5-year-old, referred to a Pediatric outpatient clinic because of growth failure, rapid weight gain and high blood pressure...